1. ZollingerRM, EllisonEH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg1955;142:709. CrossRef

2. JensenRT, NiederleB, MitryE, et al.Gastrinoma (duodenal and pancreatic). Neuroendocrinology2006;84:173. CrossRef

3. EllisonEC, JohnsonJA. The Zollinger‐Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations. Curr Probl Surg2009;46:13. CrossRef

4. StabileBE. Gastrinoma before Zollinger and Ellison. Am J Surg1997;174:232. CrossRef

5. GregoryRA, TracyHJ, FrenchJM, et al.Extraction of a gastrin‐like substance from a pancreatic tumor in a case of Zollinger‐Ellison syndrome. Lancet1960;1:1045. CrossRef

6. GregoryRA, GrossmanMI, TracyHJ, et al.Nature of the gastric secretagogue in Zollinger‐Ellison tumors. Lancet1967;2:543. CrossRef

7. GregoryRA, TracyHJ, AgarwalKL, et al.Aminoacid constitution of two gastrins isolated from Zollinger‐Ellison tumor tissue. Gut1969;10:603. CrossRef

8. McGuiganJE, TrudeauWL. Immunochemical measurement of elevated levels of gastrin in the serum of patients with pancreatic tumors of the Zollinger‐Ellison variety. N Engl J Med1968;278:1308. CrossRef

9. StrempleJF, MeadeRC. Production of antibodies to synthetic human gastrin I and radioimmunoassay of gastrin in the serum of patients with the Zollinger‐Ellison syndrome. Surgery1968;64:165.

10. JensenRT, GardnerJD. Gastrinoma. In: GoVLW, DiMagnoEP, GardnerJD, et al. (eds). The Pancreas: Biology, Pathobiology and Disease, 2nd ed. New York: Raven Press Publishing Co.; 1993: 931.

11. RehfeldJF, Friis‐HansenL, GoetzeJP, et al.The biology of cholecystokinin and gastrin peptides. Curr Top Med Chem2007;7:1154. CrossRef

12. JensenRT. Zollinger‐Ellison syndrome. In: DohertyGM, SkogseidB. (eds). Surgical Endocrinology: Clinical Syndromes. Philadelphia: Lippincott Williams & Wilkins; 2001: 291.

13. JensenRT, CadiotG, BrandiML, et al.ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology2012;95:98. CrossRef

14. ItoT, CadiotG, JensenRT. Diagnosis of Zollinger‐Ellison syndrome: increasingly difficult. World J Gastroenterol2012;18:5495. CrossRef

15. ItoT, IgarashiH, JensenRT. Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. Best Pract Res Clin Gastroenterol2012;26:737. CrossRef

16. KulkeMH, AnthonyLB, BushnellDL, et al.NANETS treatment guidelines: well‐differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas2010;39:735. CrossRef

17. KlimstraDS, ModlinIR, CoppolaD, et al.The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas2010;39:707. CrossRef

18. CapelliP, FassanM, ScarpaA. Pathology – Grading and staging of GEP‐NETs. Best Pract Res Clin Gastroenterol2012;26:705. CrossRef

19. RoyPK, VenzonDJ, ShojamaneshH, et al.Zollinger‐Ellison syndrome: clinical presentation in 261 patients. Medicine (Baltimore)2000;79:379. CrossRef

20. GibrilF, SchumannM, PaceA, et al.Multiple endocrine neoplasia type 1 and Zollinger‐Ellison syndrome. A prospective study of 107 cases and comparison with 1009 patients from the literature. Medicine (Baltimore)2004;83:43. CrossRef

21. JensenRT, BernaMJ, BinghamMD, et al.Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management and controversies. Cancer2008;113:1807. CrossRef

22. LeeWS, KohYS, KimJC, et al.Zollinger‐Ellison syndrome associated with neurofibromatosis type 1: a case report. BMC Cancer2005;5:85. CrossRef

23. SchwarzkopfG, PfistererJ. Metastasizing gastrinoma and tuberous sclerosis complex. Zentralbl Pathol1994;139:477.

24. MetzDC, ComerGM, SofferE, et al.Three‐year oral pantoprazole administration is effective for patients with Zollinger‐Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Ther2006;23:437. CrossRef

25. NortonJA, AlexanderHR, FrakerDL, et al.Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases or survival in patients with Zollinger‐Ellison syndrome (ZES). Ann Surg2004;239:617. CrossRef

26. MetzDC, JensenRT. Gastrointestinal neuroendocrine tumors:; Pancreatic endocrine tumors. Gastroenterology2008;135:1469. CrossRef

27. YaoJC, EisnerMP, LearyC, et al.Population‐based study of islet cell carcinoma. Ann Surg Oncol2007;14:3492. CrossRef

28. JensenRT. Natural history of digestive endocrine tumors. In: MignonM, ColombelJF(eds). Recent Advances in Pathophysiology and Management of Inflammatory Bowel Diseases and Digestive Endocrine Tumors. Paris, France: John Libbey Eurotext Publishing Co.; 1999: 192.

29. TaalBG, VisserO. Epidemiology of neuroendocrine tumours. Neuroendocrinology2004;80:3. CrossRef

30. HalfdanarsonTR, RubinJ, FarnellMB, et al.Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer2008;15:409. CrossRef

31. FraenkelM, KimMK, FaggianoA, et al.Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol2012;26:691. CrossRef

32. YaoJC, HassanM, PhanA, et al.One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol2008;26:3063. CrossRef

33. YuF, VenzonDJ, SerranoJ, et al.Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger‐Ellison syndrome. J Clin Oncol1999;17:615.

34. WeberHC, VenzonDJ, LinJT, et al.Determinants of metastatic rate and survival in patients with Zollinger‐Ellison syndrome: a prospective long‐term study. Gastroenterology1995;108:1637. CrossRef

35. ThomAK, NortonJA, AxiotisCA, et al.Location, incidence and malignant potential of duodenal gastrinomas. Surgery1991;110:1086.

36. GibrilF, JensenRT. Advances in evaluation and management of gastrinoma in patients with Zollinger‐Ellison syndrome. Curr Gastroenterol Rep2005;7:114. CrossRef

37. MignonM, RuszniewskiP, HaffarS, et al.Current approach to the management of tumoral process in patients with gastrinoma. World J Surg1986;10:703. CrossRef

38. FarleyDR, Van HeerdenJA, GrantCS, et al.The Zollinger‐Ellison syndrome. A collective surgical experience. Ann Surg1992;215:561. CrossRef

39. JensenRT, GardnerJD, RaufmanJP, et al.Zollinger‐Ellison syndrome: current concepts and management. Ann Intern Med1983;98:59. CrossRef

40. EllisonEH, WilsonSD. The Zollinger‐Ellison syndrome: re‐appraisal and evaluation of 260 registered cases. Ann Surg1964;160:512. CrossRef

41. StageJG, StadilF. The clinical diagnosis of the Zollinger‐Ellison syndrome. Scand J Gastroenterol Suppl1979;53:79.

42. RaufmanJP, CollinsSM, PandolSJ, et al.Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger‐Ellison syndrome. Gastroenterology1983;84:108.

43. ItoT, IgarashiH, UeharaH, et al.Pharmacotherapy of Zollinger‐Ellison syndrome. Expert Opin Pharmacother2013;14:307. CrossRef

44. ThompsonJC, LewisBG, WienerI, et al.The role of surgery in the Zollinger‐Ellison syndrome. Ann Surg1983;197:594. CrossRef

45. JensenRT. Gastrointestinal endocrine tumors. Gastrinoma. Baillieres Clin Gastroenterol1996;10:555. CrossRef

46. SchubertML. Hormonal regulation of gastric acid secretion. Curr Gastroenterol Rep2008;10:523. CrossRef

47. RoyPK, VenzonDJ, FeigenbaumKM, et al.Gastric secretion in Zollinger‐Ellison syndrome: correlation with clinical expression, tumor extent and role in diagnosis – a prospective NIH study of 235 patients and review of the literature in 984 cases. Medicine (Baltimore)2001;80:189. CrossRef

48. AoyagiT, SummerskillWH. Gastric secretion with ulcerogenic islet cell tumor. Importance of basal acid output. Arch Intern Med1966;117:667. CrossRef

49. WayL, GoldmanL, DunphyJE. Zollinger‐Ellison syndrome. An analysis of twenty‐five cases. Am J Surg1968;116:293. CrossRef

50. RichardsonCT, PetersMN, FeldmanM, et al.Treatment of Zollinger‐Ellison syndrome with exploratory laparotomy, proximal gastric vagotomy, and H2‐receptor antagonists. A prospective study. Gastroenterology1985;89:357.

51. JensenRT. Gastrinoma as a model for prolonged hypergastrinemia in man. In: WalshJH(ed). Gastrin. New York, NY: Raven Press Publishing Co.; 1993: 373.

52. WillemsG. Trophic action of gastrin on specific target cells in the gut. In: MignonM, JensenRT(eds). Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series: Frontiers of Gastrointestinal Research, Vol. 23. Basel, Switzerland: S. Karger; 1995: 30.

53. HakansonR, OscarsonJ, SundlerF. Gastrin and the trophic control of gastric mucosa. Scand J Gastroenterol1986;118:18. CrossRef

54. HakansonR, SundlerFH. Regulation of gastric endocrine cell proliferation. In: WalshJH(ed). Gastrin. New York: Raven Press, Ltd.; 1993: 307.

55. HakansonR, EkelundM, SundlerF. Activation and proliferation of gastric endocrine cells. In: FalkmerS, HakansonR, SundlerF(eds). Evolution and Tumor Pathology of the Neuroendocrine System. Amsterdam: Elsevier; 1984: 371.

56. NeuburgerP, LewinM, RechercheCD, et al.Parietal and chief cell population in four cases of the Zollinger‐Ellison syndrome. Gastroenterology1972;63:937.

57. PolacekMA, EllisonEH. Parietal cell mass and gastric acid secretion in the Zollinger‐Ellison syndrome. Surgery1966;60:606.

58. IsenbergJI, WalshJH, GrossmanMI. Zollinger‐Ellison syndrome. Gastroenterology1973;65:140.

59. D'AddaT, CorletoV, PilatoFP, et al.Quantitative ultrastructure of endocrine cells of oxyntic mucosa in Zollinger‐Ellison syndrome. Correspondence with light microscopic findings. Gastroenterology1990;99:17.

60. MatonPN, LackEE, CollenMJ, et al.The effect of Zollinger‐Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Gastroenterology1990;99:943.

61. LehyT, MignonM, CadiotG, et al.Gastric endocrine cell behavior in Zollinger‐Ellison patients upon long‐term potent antisecretory treatment. Gastroenterology1989;96:1029.

62. WaldumHL. Gastrin – Physiology and pathophysiologial role: clinical consequences. Dig Dis1995:25. CrossRef

63. CreutzfeldtW. The achlorhydria‐carcinoid sequence: role of gastrin. Digestion1988;39:61. CrossRef

64. PeghiniPL, AnnibaleB, AzzoniC, et al.Effect of chronic hypergastrinemia on human enterochromaffin‐like cells: insights from patients with sporadic gastrinomas. Gastroenterology2002;123:68. CrossRef

65. BernaMJ, AnnibaleB, MarignaniM, et al.A prospective study of gastric carcinoids and enterochromaffin‐like cells changes in Multple Endocrine Neoplasia Type 1 and Zollinger‐Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab2008;93:1582. CrossRef

66. SolciaE, BordiC, CreutzfeldtW, et al.Histopathological classification of nonantral gastric endocrine growths in man. Digestion1988;41:185. CrossRef

67. RindiG, LuinettiO, CornaggiaM, et al.Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology1993;104:994.

68. CadiotG, LehyT, RuszniewskiP, et al.Gastric endocrine cell evolution in patients with Zollinger‐Ellison syndrome. Influence of gastrinoma growth and long‐term omeprazole treatment. Dig Dis Sci1993;38:1307. CrossRef

69. LehyT, CadiotG, MignonM, et al.Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger‐Ellison syndrome. Gut1992;33:1275. CrossRef

70. FeurleGE. Argyrophil cell hyperplasia and a carcinoid tumour in the stomach of a patient with sporadic Zollinger‐Ellison syndrome. Gut1994;35:275. CrossRef

71. CadiotG, VissuzaineC, PotetF, et al.Fundic argyrophil carcinoid tumor in a patient with sporadic‐type Zollinger‐Ellison syndrome. Dig Dis Sci1995;40:1275. CrossRef

72. JensenRT, DoppmanJL, GardnerJD. Gastrinoma. In: GoVLW, BrooksFA, DiMagnoEP, et al. (eds). The Exocrine Pancreas: Biology, Pathobiology and Disease, 1st ed. New York: Raven Press; 1986: 727.

73. KloppelG, AnlaufM. Gastrinoma – morphological aspects. Wien Klin Wochenschr2007;119:579. CrossRef

74. SogaJ, YakuwaY. The gastrinoma/Zollinger‐Ellison syndrome: statistical evaluation of a Japanese series of 359 cases. J Hep Bil Pancr Surg1998;5:77. CrossRef

75. ZollingerRM, EllisonEC, FabriPJ, et al.Primary peptic ulcerations of the jejunum associated with islet cell tumors. Twenty‐five‐year appraisal. Ann Surg1980;192:422. CrossRef

76. DeveneyCW, DeveneyKS, StarkD, et al.Resection of gastrinomas. Ann Surg1983;198:546. CrossRef

77. OberhelmanHAJr, NelsenTS, JohnsonAN, et al.Ulcerogenic tumors of the duodenum. Ann Surg1961;153:214. CrossRef

78. HofmannJW, FoxPS, WilsonSD. Duodenal wall tumors and the Zollinger‐Ellison syndrome. Surgical management. Arch Surg1973;107:334. CrossRef

79. NortonJA, FrakerDL, AlexanderHR, et al.Surgery to cure the Zollinger‐Ellison syndrome. N Engl J Med1999;341:635. CrossRef

80. NortonJA, DoppmanJL, CollenMJ, et al.Prospective study of gastrinoma localization and resection in patients with Zollinger‐Ellison syndrome. Ann Surg1986;204:468. CrossRef

81. NortonJA, DoppmanJL, JensenRT. Curative resection in Zollinger‐Ellison syndrome: results of a 10‐year prospective study. Ann Surg1992;215:8. CrossRef

82. SuggSL, NortonJA, FrakerDL, et al.A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Ann Surg1993;218:138. CrossRef

83. RaufmanJP, KasbekarDK, JensenRT, et al.Potentiation of pepsinogen secretion from dispersed glands from rat stomach. Am J Physiol1983;245:G525.

84. ThompsonNW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic‐duodenal disease. Results in the treatment of 40 patients with Zollinger‐Ellison syndrome, hypoglycaemia or both. J Intern Med1998;243:495. CrossRef

85. HowardTJ, ZinnerMJ, StabileBE, et al.Gastrinoma excision for cure. A prospective analysis. Ann Surg1990;211:9. CrossRef

86. CadiotG, LebtahiR, SardaL, et al.Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Gastroenterology1996;111:845. CrossRef

87. NortonJA, HarrisEJ, ChenY, et al.Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg2011;146:724. CrossRef

88. NortonJA, FrakerDL, AlexanderHR, et al.Value of surgery in patients with negative imaging and sporadic Zollinger‐Ellison syndrome. Ann Surg2012;256:509. CrossRef

89. GibrilF, CurtisLT, TermaniniB, et al.Primary cardiac gastrinoma causing Zollinger‐Ellison syndrome. Gastroenterology1997;112:567. CrossRef

90. Abou‐SaifA, LeiJ, McDonaldTJ, et al.A new cause of Zollinger‐Ellison syndrome: non‐small cell lung cancer. Gastroenterology2001;120:1271. CrossRef

91. NortonJA, AlexanderHA, FrakerDL, et al.Possible primary lymph node gastrinomas: occurrence, natural history and predictive factors: a prospective study. Ann Surg2003;237:650.

92. ArnoldWS, FrakerDL, AlexanderHR, et al.Apparent lymph node primary gastrinoma. Surgery1994;116:1123.

93. ItoT, JensenRT. Primary hepatic gastrinoma: an unusual case of zollinger‐ellison syndrome. Gastroenterol Hepatol (N Y)2010;6:57.

94. PerrierND, BattsKP, ThompsonGB, et al.An immunohistochemical survey for neuroendocrine cells in regional pancreatic lymph nodes: a plausible explanation for primary nodal gastrinomas?Surgery1995;118:957. CrossRef

95. AtemaJJ, AmriR, BuschOR, et al.Surgical treatment of gastrinomas: a single‐centre experience. HPB (Oxford)2012;14:833. CrossRef

96. AnlaufM, EnosawaT, HenoppT, et al.Primary lymph node gastrinoma or occult duodenal microgastrinoma with lymph node metastases in a MEN1 patient: the need for a systematic search for the primary tumor. Am J Surg Pathol2008;32:1101. CrossRef

97. HerrmannME, CieslaMC, ChejfecG, et al.Primary Nodal gastrinomas – an immunohistochemical study in support of a theory. Arch Pathol Lab Med2000;124:832.

98. StabileBE, MorrowDJ, PassaroEJr. The gastrinoma triangle: operative implications. Am J Surg1984;147:25. CrossRef

99. DelcoreRJr, CheungLY, FriesenSR. Characteristics of duodenal wall gastrinomas. Am J Surg1990;160:621. CrossRef

100. CreutzfeldtW, ArnoldR, CreutzfeldtC, et al.Pathomorphologic, biochemical and diagnostic aspects of gastrinomas (Zollinger‐Ellison syndrome). Hum Pathol1975;6:47. CrossRef

101. MetzDC, JensenRT, BaleAE, et al.Multiple endocrine neoplasia type 1: clinical features and management. In: BilezekianJP, LevineMA, MarcusR(eds). The Parathyroids. New York: Raven Press Publishing Co.; 1994: 591.

102. KloppelG, SchroderS, HeitzPU. Histopathology and immunopathology of pancreatic endocrine tumors. In: MignonM, JensenRT(eds). Endocrine Tumors of the Pancreas: Recent advances in research and management. Series: Frontiers of Gastrointestinal Research, Vol. 23. Basel, Switzerland: S. Karger; 1995: 99.

103. DonowC, Pipeleers‐MarichalM, SchroderS, et al.Surgical pathology of gastrinoma: site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy. Cancer1991;68:1329. CrossRef

104. NortonJA, JensenRT. Current surgical management of Zollinger‐Ellison syndrome (ZES) in patients without multiple endocrine neoplasia‐type 1 (MEN1). Surg Oncol2003;12:145. CrossRef

105. NortonJA, DohertyGD, FrakerDL, et al.Surgical treatment of localized gastrinoma within the liver: a prospective study. Surgery1998;124:1145. CrossRef

106. ZogakisTG, GibrilF, LibuttiSK, et al.Management and outcome of patients with sporadic gastrinomas arising in the duodenum. Ann Surg2003;238:42.

107. GibrilF, DoppmanJL, ReynoldsJC, et al.Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and MRI in their detection, their frequency, location and effect of their detection on management. J Clin Oncol1998;16:1040.

108. LebtahiR, CadiotG, DelahayeN, et al.Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy. J Nucl Med1999;40:1602.

109. JensenRT. Endocrine neoplasms of the pancreas. In: YamadaT, AlpersDH, KallooAN, et al. (eds). Textbook of Gastroenterology, 5th ed. Oxford, England: Wiley Blackwell; 2009: 1875.

110. Kos‐KudlaB, O'TooleD, FalconiM, et al.ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. Neuroendocrinology2010;91:341. CrossRef

111. LeboulleuxS, DromainC, VataireAL, et al.Prediction and diagnosis of bone metastases in well‐differentiated gastro‐entero‐pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy. J Clin Endocrinol Metab2008;93:3021. CrossRef

112. HeitzPU, KasperM, PolakJM, et al.Pancreatic endocrine tumors. Immunohistochemial analysis of 125 tumors. Hum Pathol1982;13:263. CrossRef

113. ChiangHC, O'DorisioTM, HuangSC, et al.Multiple hormone elevations in patients with Zollinger‐Ellison syndrome: prospective study of clinical significance and of the development of a second symptomatic pancreatic endocrine tumor syndrome. Gastroenterology1990;99:1565.

114. KlimstraDS. Pathology reporting of neuroendocrine tumors: essential elements for accurate diagnosis, classification, and staging. Semin Oncol2013;40:23. CrossRef

115. KloppelG. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer2011;18:S1. CrossRef

116. RindiG, FalconiM, KlersyC, et al.TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst2012;104:764. CrossRef

117. RehfeldJF, van SolingeWW. The tumor biology of gastrin and cholecystokinin. Adv Cancer Res1994;63:295. CrossRef

118. WalshJH. Gastrin. In: WalshJH, DockrayGJ(eds). Gut Peptides. New York: Raven Press; 1994: 75.

119. BardramL. Progastrin in pancreas and the Zollinger‐Ellison syndrome. Scand J Gastroenterol1990;25:1185. CrossRef

120. BardramL. Progastrin in serum from Zollinger‐Ellison patients. An indicator of malignancy?Gastroenterology1990;98:1420.

121. d'HerbomezM, Do CaoC, VezzosiD, et al.Chromogranin A assay in clinical practice. Ann Endocrinol (Paris)2010;71:274. CrossRef

122. LawrenceB, GustafssonBI, KiddM, et al.The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am2011;40:111, viii. CrossRef

123. NobelsFR, KwekkeboomDJ, BouillonR, et al.Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur J Clin Invest1998;28:431. CrossRef

124. GoebelSU, SerranoJ, YuF, et al.Prospective study of the value of serum chromogranin A or serum gastrin levels in assessment of the presence, extent, or growth of gastrinomas. Cancer1999;85:1470. CrossRef

125. NobelsFR, KwekkeboomDJ, CoopmansW, et al.Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron‐specific enolase and the alpha‐subunit of glycoprotein hormones. J Clin Endocrinol Metab1997;82:2622.

126. ItoT, IgarashiH, JensenRT. Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors?Pancreas2012;41:505. CrossRef

127. Abou‐SaifA, GibrilF, OjeaburuJV, et al.Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Cancer2003;98:249. CrossRef

128. RainesD, ChesterM, DieboldAE, et al.A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans. Pancreas2012;41:508. CrossRef

129. SyversenU, MignonM, BonfilsS, et al.Chromogranin A and pancreastatin‐like immunoreactivity in serum of gastrinoma patients. Acta Oncol1993;32:161. CrossRef

130. StabileBE, HowardTJ, PassaroEJr, et al.Source of plasma chromogranin A elevation in gastrinoma patients. Arch Surg1990;125:451. CrossRef

131. HirschowitzBI, WorthingtonJ, MohnenJ, et al.Chromogranin A in patients with acid hypersecretion and/or hypergastrinaemia. Aliment Pharmacol Ther2007;26:869. CrossRef

132. IsenbergJI, WalshJH, PassaroEJr, et al.Unusual effect of secretin on serum gastrin, serum calcium and gastric acid secretion in a patient with suspected Zollinger‐Ellison syndrome. Gastroenterology1972;62:626.

133. McGuiganJE, WolfeMM. Secretin injection test in the diagnosis of gastrinoma. Gastroenterology1980;79:1324.

134. DeveneyCW, DeveneyKS, JaffeBM, et al.Use of calcium and secretin in the diagnosis of gastrinoma (Zollinger‐Ellison syndrome). Ann Intern Med1977;87:680. CrossRef

135. FruchtH, HowardJM, SlaffJI, et al.Secretin and calcium provocative tests in the Zollinger‐Ellison syndrome: a prospective study. Ann Intern Med1989;111:713. CrossRef

136. BernaMJ, HoffmannKM, LongSH, et al.Serum gastrin in Zollinger‐Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore)2006;85:331. CrossRef

137. LamersCB, Van TongerenJHM. Comparative study of the value of calcium, secretin, and meal stimulated increase in serum gastrin in the diagnosis of the Zollinger‐Ellison syndrome. Gut1977;18:128. CrossRef

138. ShibataC, FunayamaY, FukushimaK, et al.Role of selective arterial secretin injection test in treatment of gastrinoma. Hepatogastroenterology2006;53:960.

139. PassaroEJr, BassoN, WalshJH. Calcium challenge in the Zollinger‐Ellison syndrome. Surgery1972;72:60.

140. FruchtH, HowardJM, StarkHA, et al.Prospective study of the standard meal provocative test in Zollinger‐Ellison syndrome. Am J Med1989;87:528. CrossRef

141. RuszniewskiP, RamdaniA, CadiotG, et al.Long‐term treatment with octreotide in patients with the Zollinger‐Ellison syndrome. Eur J Clin Invest1993;23:296. CrossRef

142. AuernhammerCJ, GokeB. Medical treatment of gastrinomas. Wien Klin Wochenschr2007;119:609. CrossRef

143. BradyCEIII.Secretin provocation test in the diagnosis of Zollinger‐Ellison syndrome. Am J Gastroenterol1991;86:129.

144. LongSH, BernaMJ, ThillM, et al.Secretin‐receptor and secretin‐receptor‐variant expression in gastrinomas: correlation with clinical and tumoral features and secretin and calcium provocative test results. J Clin Endocrinol Metab2007;92:4394. CrossRef

145. BradyCE, UttsSJ, DevJ. Secretin provocation in normal and duodenal ulcer subjects. Is the gastrin rise in Zollinger‐Ellison syndrome paradoxic or exaggeration?Dig Dis Sci1987;32:232. CrossRef

146. DingWQ, KuntzS, BohmigM, et al.Dominant negative action of an abnormal secretin receptor arising from mRNA missplicing in a gastrinoma. Gastroenterology2002;122:500. CrossRef

147. ReubiJC, KvolsLK, WaserB, et al.Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res1990;50:5969.

148. KrenningEP, KwekkeboomDJ, BakkerWH, et al.Somatostatin receptor scintigraphy with [111In‐DTPA‐D‐Phe1]‐ and [123I‐Tyr3]‐octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med1993;20:716. CrossRef

149. GoebelSU, PeghiniPL, GoldsmithPK, et al.Expression of the calcium‐sensing receptor in gastrinomas. J Clin Endocrinol Metab2000;85:4131. CrossRef

150. ItamiA, KatoM, KomotoI, et al.Human gastrinoma cells express calcium‐sensing receptor. Life Sci2001;70:119. CrossRef

151. Elouaer‐BlancL, SobhaniI, RuszniewskiP, et al.Gastrin secretion by gastrinoma cells in long‐term culture. Am J Physiol1988;255:G596.

152. GowerWRJr, EllisonEC, KnierimTH, et al.Gastrinoma in vitro: morphological and physiological studies of primary cell cultures. Gastroenterology1990;98:936. CrossRef

153. ImamuraM, AdachiH, TakahashiK, et al.Gastrin release from gastrinoma cells stimulated with secretin. Dig Dis Sci1982;27:1130. CrossRef

154. ChibaT, YamataniT, YamaguchiA, et al.Mechanism for increase of gastrin release by secretin in Zollinger‐Ellison syndrome. Gastroenterology1989;96:1439.

155. EllisonEC, GowerWR, ElkhammasE, et al.Characterization of the in vivo and in vitro inhibition of gastrin secretion from gastrinoma by a somatostatin analogue (SMS 201‐995). Am J Med1986;81:56. CrossRef

156. SawickiMP, WanYJ, JohnsonCL, et al.Loss of heterozygosity on chromosome 11 in sporadic gastrinomas. Hum Genet1992;89:445. CrossRef

157. VortmeyerAO, HuangS, LubenskyI, et al.Non‐islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab2004;89:1934. CrossRef

158. LarssonLI, RehfeldJF, GoltermannN. Gastrin in the human fetus: distribution and molecular forms of gastrin in the antro‐pyloric gland area, duodenum and pancreas. Scand J Gastroenterol1977;12:869. CrossRef

159. PassaroEJr, HowardTJ, SawickiMP, et al.The origin of sporadic gastrinomas within the gastrinoma triangle: a theory. Arch Surg1998;133:13. CrossRef

160. SolciaE, CapellaC, BuffaR, et al.Endocrine cells of the gastrointestinal tract and related tumors. Pathobiol Annu1979;9:163.

161. HowardTJ, SawickiMP, StabileBE, et al.Biologic behavior of sporadic gastrinoma located to the right and left of the superior mesenteric artery. Am J Surg1993;165:101. CrossRef

162. SolciaE, CapellaC, BuffaR, et al.Pathology of the Zollinger‐Ellison syndrome. Prog Surg Pathol1980;I:119.

163. KloppelG, AnlaufM, PerrenA. Endocrine precursor lesions of gastroenteropancreatic neuroendocrine tumors. Endocr Pathol2007;18:150. CrossRef

164. AnlaufM, PerrenA, HenoppT, et al.Allelic deletion of the MEN1 gene in duodenal gastrin and somatostatin cell neoplasms and their precursor lesions. Gut2007;56:637. CrossRef

165. PerrenA, AnlaufM, HenoppT, et al.Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. J Clin Endocrinol Metab2007;92:1118. CrossRef

166. GrandeE, CapdevilaJ, BarriusoJ, et al.Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?Cancer Metastasis Rev2012;31:47. CrossRef

167. GibrilF, VenzonDJ, OjeaburuJV, et al.Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab2001;86:5282. CrossRef

168. StabileBE, PassaroEJr. Benign and malignant gastrinoma. Am J Surg1985;49:144. CrossRef

169. SutliffVE, DoppmanJL, GibrilF, et al.Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol1997;15:2420.

170. ObergK. The genetics of neuroendocrine tumors. Semin Oncol2013;40:37. CrossRef

171. ZhangJ, FrancoisR, IyerR, et al.Current understanding of the molecular biology of pancreatic neuroendocrine tumors. J Natl Cancer Inst2013;105:1005. CrossRef

172. JiaoY, ShiC, EdilBH, et al.DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science2011;331:1199. CrossRef

173. DuerrEM, ChungDC. Molecular genetics of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab2007;21:1. CrossRef

174. CorletoVD, Delle FaveG, JensenRT. Molecular insights into gastrointestinal neuroendocrine tumors: importance and recent advances. Dig Liver Dis2002;34:668. CrossRef

175. HuW, FengZ, ModicaI, et al.Gene amplifications in well‐differentiated pancreatic neuroendocrine tumors inactivate the p53 pathway. Genes Cancer2010;1:360. CrossRef

176. TangLH, ContractorT, ClausenR, et al.Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6. Clin Cancer Res2012;18:4612. CrossRef

177. ItoT, IgarashiH, UeharaH, et al.Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger‐Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore)2013;92:135. CrossRef

178. ThakkerRV. Multiple endocrine neoplasia type 1. Endocrinol Metab Clin North Am2000;29:541. CrossRef

179. ChandrasekharappaSC, GuruSC, ManickamP, et al.Positional cloning of the gene for multiple endocrine neoplasia‐Type 1. Science1997;276:404. CrossRef

180. ThakkerRV. Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab2010;24:355. CrossRef

181. FalchettiA, MariniF, LuziE, et al.Multiple endocrine neoplasms. Best Pract Res Clin Rheumatol2008;22:149. CrossRef

182. GoebelSU, HeppnerC, BurnsAD, et al.Geneotype/phenotype correlations of MEN1 gene mutations in sporadic gastrinoma. J Clin Endocrinol Metab2000;85:116. CrossRef

183. AmatoE, BarbiS, MalpeliG, et al.Chromosome 3p alterations in pancreatic endocrine neoplasia. Virchows Arch2011;458:39. CrossRef

184. CapursoG, FestaS, ValenteR, et al.Molecular pathology and genetics of pancreatic endocrine tumours. J Mol Endocrinol2012;49:R37. CrossRef

185. WolinEM. PI3K/Akt/mTOR Pathway inhibitors in the therapy of pancreatic neuroendocrine tumors. Cancer Lett2013;335:1. CrossRef

186. YaoJC, ShahMH, ItoT, et al.Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med2011;364:514. CrossRef

187. MissiagliaE, DalaiI, BarbiS, et al.Pancreatic endocrine tumors: expression profiling evidences a role for AKT‐mTOR pathway. J Clin Oncol2010;28:245. CrossRef

188. SerraS, ZhengL, HassanM, et al.The FGFR4‐G388R single‐nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy. Cancer Res2012;72:5683. CrossRef

189. MignonM, JaisP, CadiotG, et al.Clinical features and advances in biological diagnostic criteria for Zollinger‐Ellison syndrome. In: MignonM, JensenRT(eds). Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series: Frontiers of Gastrointestinal Research, Vol. 23. Basel, Switzerland: S. Karger; 1995: 223.

190. JensenRT. Overview of chronic diarrhea caused by functional neuroendocrine neoplasms. Semin Gastrointest Dis1999;10:156.

191. GreenbergRS, BaumgartenDA, ClarkWS, et al.Prognostic factors for gastrointestinal and bronchopulmonary carcinoid tumors. Cancer1987;60:2476. CrossRef

192. MillerLS, VinayekR, FruchtH, et al.Reflux esophagitis in patients with Zollinger‐Ellison syndrome. Gastroenterology1990;98:341. CrossRef

193. BondesonAG, BondesonL, ThompsonNW. Stricture and perforation of the esophagus: overlooked threats in the Zollinger‐Ellison syndrome. World J Surg1990;14:361. CrossRef

194. NortonJA, MelcherML, GibrilF, et al.Gastric carcinoid tumors in multiple endocrine neoplasia‐1 patients with Zollinger‐Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgery. Surgery2004;136:1267. CrossRef

195. HoffmannKM, GibrilF, EntsuahLK, et al.Patients with multiple endocrine neoplasia type 1 with gastrinomas have an increased risk of severe esophageal disease including stricture and the premalignant condition, Barrett's esophagus. J Clin Endocrinol Metab2006;91:204. CrossRef

196. BenyaRV, MetzDC, VenzonDJ, et al.Zollinger‐Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia‐type 1. Am J Med1994;97:436. CrossRef

197. KimuraW, KurodaA, MoriokaY. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci1991;36:933. CrossRef

198. ThakkerRV, NeweyPJ, WallsGV, et al.Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab2012;97:2990. CrossRef

199. LangerP, WildA, CelikI, et al.Prospective controlled trial of a standardized meal stimulation test in the detection of pancreaticoduodenal endocrine tumours in patients with multiple endocrine neoplasia type 1. Br J Surg2001;88:1403. CrossRef

200. BettsJB, O'MalleyBP, RosenthalFD. Hyperparathyroidism: a prerequisite for Zollinger‐Ellison syndrome in multiple endocrine adenomatosis type I–report of a further family and a review of the literature. Q J Med1980;193:69.

201. MignonM, CadiotG. Diagnostic and therapeutic criteria in patients with Zollinger‐Ellison syndrome and multiple endocrine neoplasia type 1. J Intern Med1998;243:489. CrossRef

202. MetzDC. Diagnosis of the Zollinger‐Ellison syndrome. Clin Gastroenterol Hepatol2012;10:126. CrossRef

203. OsefoN, ItoT, JensenRT. Gastric acid hypersecretory states: recent insights and advances. Curr Gastroenterol Rep2009;11:433. CrossRef

204. RehfeldJF, GingrasMH, BardramL, et al.The Zollinger‐Ellison syndrome and mismeasurement of gastrin. Gastroenterology2011;140:1444. CrossRef

205. PoitrasP, GingrasMH, RehfeldJF. The Zollinger‐Ellison syndrome: dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol2012;10:199. CrossRef

206. BanaschM, SchmitzF. Diagnosis and treatment of gastrinoma in the era of proton pump inhibitors. Wien Klin Wochenschr2007;119:573. CrossRef

207. MurugesanSV, VarroA, PritchardDM. Review article: strategies to determine whether hypergastrinaemia is due to Zollinger Ellison syndrome rather than a more common benign cause. Aliment Pharmacol Ther2009;29:1055. CrossRef

208. CorletoVD, AnnibaleB, GibrilF, et al.Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger‐Ellison syndrome?Aliment Pharmacol Ther2001;15:1555. CrossRef

209. ItoT, IgarashiH, JensenRT. Zollinger‐Ellison syndrome: recent advances and controversies. Curr Opin Gastroenterol2013;29:650. CrossRef

210. PoitrasP, GingrasMH, RehfeldJF. Secretin stimulation test for gastrin release in Zollinger‐Ellison syndrome: to do or not to do?Pancreas2013;42:903. CrossRef

211. SaeedZA, EvansDJJr, EvansDG, et al.Helicobacter pylori and the Zollinger‐Ellison syndrome. Dig Dis Sci1991;36:15. CrossRef

212. FichA, TalleyNJ, ShorterRG, et al.Zollinger‐Ellison syndrome. Relation to Helicobacter pylori‐associated chronic gastritis and gastric acid secretion. Dig Dis Sci1991;36:10. CrossRef

213. WeberHC, VenzonDJ, JensenRT, et al.Studies on the interrelation between Zollinger‐Ellison syndrome, Helicobacter pylori and proton pump inhibitor therapy. Gastroenterology1997;112:84. CrossRef

214. NortonJA, CorneliusMJ, DoppmanJL, et al.Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger‐Ellison syndrome and multiple endocrine neoplasia Type I: a prospective study. Surgery1987;102:958.

215. NortonJA, VenzonDJ, BernaMJ, et al.Prospective study of surgery for primary hyperaparathyroidism (HPT) in Multiple Endocrine Neoplasia type 1 (MEN1), and Zollinger‐Ellison syndrome (ZES): longterm outcome of a more virulent form of HPT. Ann Surg2008;247:501. CrossRef

216. JensenRT. Management of the Zollinger‐Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med1998;243:477. CrossRef

217. FishbeynVA, NortonJA, BenyaRV, et al.Assessment and prediction of long‐term cure in patients with Zollinger‐Ellison syndrome: the best approach. Ann Intern Med1993;119:199. CrossRef

218. BernaMJ, HoffmannKM, SerranoJ, et al.Serum gastrin in Zollinger‐Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore)2006;85:295. CrossRef

219. WeberHC, WaltersJ, LeytonJ, et al.A bombesin receptor subtype‐3 peptide increases nuclear oncogene expression in a MEK‐1 dependent manner in human lung cancer cells. Eur J Pharmacol2001;412:13. CrossRef

220. MetzDC, PisegnaJR, FishbeynVA, et al.Currently used doses of omeprazole in Zollinger‐Ellison syndrome are too high. Gastroenterology1992;103:1498.

221. HirschowitzBI, MohnenJ, ShawS. Long‐term treatment with lansoprazole for patients with Zollinger‐Ellison syndrome. Aliment Pharmacol Ther1996;10:507. CrossRef

222. JensenRT. Use of omeprazole and other proton pump inhibitors in the Zollinger‐Ellison syndrome. In: OlbeL(ed). Milestones in Drug Therapy. Basel, Switzerland: Birkhauser Verlag AG Publish. Co.; 1999: 205.

223. MetzDC, StraderDB, OrbuchM, et al.Use of omeprazole in Zollinger‐Ellison: a prospective nine‐year study of efficacy and safety. Aliment Pharmacol Ther1993;7:597. CrossRef

224. VinayekR, HowardJM, MatonPN, et al.Famotidine in the therapy of gastric hypersecretory states. Am J Med1986;81:49. CrossRef

225. JensenRT, CollenMJ, McArthurKE, et al.Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric acid hypersecretory states. Am J Med1984;77:90.

226. OhDS, WangHS, OhningGV, et al.Validation of a new endoscopic technique to assess acid output in Zollinger‐Ellison syndrome. Clin Gastroenterol Hepatol2006;4:1467. CrossRef

227. GibrilF, ReynoldsJC, ChenCC, et al.Specificity of somatostatin receptor scintigraphy: a prospective study and the effects of false positive localizations on management in patients with gastrinomas. J Nucl Med1999;40:539.

228. MetzDC, WeberHC, OrbuchM, et al.Helicobacter pylori infection: a reversible cause of hypergastrinemia and hyperchlorhydria which can mimic Zollinger‐Ellison syndrome. Dig Dis Sci1995;40:153. CrossRef

229. ChuS, SchubertML. Gastric secretion. Curr Opin Gastroenterol2012;28:587. CrossRef

230. MalfertheinerP. The intriguing relationship of Helicobacter pylori infection and acid secretion in peptic ulcer disease and gastric cancer. Dig Dis2011;29:459. CrossRef

231. DeveneyCW, DeveneyKE, JonesS, et al.Calcium and secretin tests in diagnosis of gastrinoma. Gastroenterology1976;70:968.

232. AnnibaleB, RindiG, D'AmbraG, et al.Antral gastrin cell hyperfunction and helicobacter pylori infection. Aliment Pharmacol Ther1996;10:607. CrossRef

233. ShibataC, KakyoM, KinouchiM, et al.Criteria for the glucagon provocative test in the diagnosis of gastrinoma. Surg Today2012.

234. FeldmanM, SchillerLR, WalshJH, et al.Positive intravenous secretin test in patients with achlorhydria‐related hypergastrinemia. Gastroenterology1987;93:59.

235. ShahP, SinghMH, YangYX, et al.Hypochlorhydria and achlorhydria are associated with false‐positive secretin stimulation testing for Zollinger‐Ellison syndrome. Pancreas2013;42:932. CrossRef

236. LeungD, SchwartzL. Imaging of neuroendocrine tumors. Semin Oncol2013;40:109. CrossRef

237. SundinA. Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol2012;26:803. CrossRef

238. ItoT, IgarashiH, JensenRT. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol2012;47:941. CrossRef

239. KloseKJ, HeverhagenJT. Localisation and staging of gastrin producing tumours using cross‐sectional imaging modalities. Wien Klin Wochenschr2007;119:588. CrossRef

240. RockallAG, ReznekRH. Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab2007;21:43. CrossRef

241. ChernerJA, DoppmanJL, NortonJA, et al.Selective venous sampling for gastrin to localize gastrinomas. A prospective study. Ann Intern Med1986;105:841. CrossRef

242. KrudyAG, DoppmanJL, JensenRT, et al.Localization of islet cell tumors by dynamic CT: comparison with plain CT, arteriography, sonography and venous sampling. Am J Roentgenol1984;143:585. CrossRef

243. DoppmanJL, MillerDL, ChangR, et al.Gastrinomas: localization by means of selective intraarterial injection of secretin. Radiology1990;174:25. CrossRef

244. MetzDC, JensenRT. Advances in gastric antisecretory therapy in Zollinger‐Ellison syndrome. In: MignonM, JensenRT(eds). Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series: Frontiers of Gastrointestinal Research, Vol. 23. Basel, Switzerland: S. Karger; 1995: 240.

245. SundinA. Imaging of neuroendocrine tumors. Expert Opin Med Diagn2012;6:473. CrossRef

246. OrbuchM, DoppmanJL, StraderDB, et al.Imaging for pancreatic endocrine tumor localization: recent advances. In: MignonM, JensenRT(eds). Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, Vol. 23. Basel, Switzerland: S. Karger; 1995: 268.

247. GibrilF, JensenRT. Diagnostic uses of radiolabelled somatostatin‐receptor analogues in gastroenteropancreatic endocrine tumors. Dig Liver Dis2004;36:S106. CrossRef

248. StraderDB, DoppmanJL, OrbuchM, et al.Functional localization of pancreatic endocrine tumors. In: MignonM, JensenRT(eds). Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series: Frontiers of Gastrointestinal Research, Vol. 23. Basel, Switzerland: Karger Publishing Co.; 1995: 282.

249. ImamuraM, TakahashiK. Use of selective arterial secretin injection test to guide surgery in patients with Zollinger‐Ellison syndrome. World J Surg1993;17:433. CrossRef

250. ThomAK, NortonJA, DoppmanJL, et al.Prospective study of the use of intraarterial secretin injection and portal venous sampling to localize duodenal gastrinomas. Surgery1992;112:1002.

251. el‐OmarEM, PenmanID, ArdillJE, et al.Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology1995;109:681. CrossRef

252. KwekkeboomDJ, KamBL, Van EssenM, et al.Somatostatin‐receptor‐based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer2010;17:R53. CrossRef

253. BeheM, GotthardtM, BehrTM. Imaging of gastrinomas by nuclear medicine methods. Wien Klin Wochenschr2007;119:593. CrossRef

254. ObergKE, ReubiJC, KwekkeboomDJ, et al.Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology2010;139:742, 753. CrossRef

255. GibrilF, ReynoldsJC, DoppmanJL, et al.Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: a prospective study. Ann Intern Med1996;125:26. CrossRef

256. AlexanderHR, FrakerDL, NortonJA, et al.Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger‐Ellison syndrome. Ann Surg1998;228:228. CrossRef

257. TanEH, TanCH. Imaging of gastroenteropancreatic neuroendocrine tumors. World J Clin Oncol2011;2:28. CrossRef

258. SrirajaskanthanR, KayaniI, QuigleyAM, et al.The role of 68Ga‐DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In‐DTPA‐octreotide scintigraphy. J Nucl Med2010;51:875. CrossRef

259. ObergK. Gallium‐68 somatostatin receptor PET/CT: is it time to replace (111)Indium DTPA octreotide for patients with neuroendocrine tumors?Endocrine2012;42:3. CrossRef

260. BartonJC, HirschowitzBI, MatonPN, et al.Bone metastases in malignant gastrinoma. Gastroenterology1986;91:1179.

261. RuszniewskiP, AmouyalP, AmouyalG, et al.Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger‐Ellison syndrome. Surgery1995;117:629. CrossRef

262. RoschT, LightdaleCJ, BotetJF, et al.Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med1992;326:1721. CrossRef

263. NortonJA, JensenRT. Resolved and unresolved controversies in the surgical management of patients with Zollinger‐Ellison syndrome. Ann Surg2004;240:757. CrossRef

264. ThompsonNW, CzakoPF, FrittsLL, et al.Role of endoscopic ultrasonography in the localization of insulinomas and gastrinomas. Surgery1994;116:1131.

265. DelaneyJP, JacobsonME. Multiple endocrine adenomatosis. Minn Med1968;51:1731.

266. Thomas‐MarquesL, MuratA, DelemerB, et al.Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol2006;101:266. CrossRef

267. KannPH, BalakinaE, IvanD, et al.Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Endocr Relat Cancer2006;13:1195. CrossRef

268. FoxPS, HofmannJW, WilsonSD, et al.Surgical management of the Zollinger‐Ellison syndrome. Surg Clin North Am1974;54:395.

269. GrahamDY, LewGM, LechagoJ. Antral G‐cell and D‐cell numbers in Helicobacter pylori infection: effect of H. pylori eradication. Gastroenterology1993;104:1655.

270. MalageladaJR, EdisAJ, AdsonMA, et al.Medical and surgical options in the management of patients with gastrinoma. Gastroenterology1983;84:1524.

271. FranzRC, PenzhornHO. Is total gastrectomy still a viable option in the management of patients with the Zollinger‐Ellison syndrome?S Afr J Surg2007;45:58.

272. RichardsonCT, FeldmanM, McClellandRN, et al.Effect of vagotomy in Zollinger‐Ellison syndrome. Gastroenterology1979;77:682.

273. McArthurKE, RichardsonCT, BarnettCC, et al.Laparotomy and proximal gastric vagotomy in Zollinger‐Ellison syndrome: results of a 16‐year prospective study. Am J Gastroenterol1996;91:1104.

274. McCarthyDM, PeikinSR, LopatinRN, et al.Hyperparathyroidism a reversible cause of cimetidine‐resistant gastric hypersecretion. Br Med J1979;1:1765. CrossRef

275. PisegnaJR, NortonJA, SlimakGG, et al.Effects of curative resection on gastric secretory function and antisecretory drug requirement in the Zollinger‐Ellison syndrome. Gastroenterology1992;102:767.

276. OjeaburuJV, ItoT, CrafaP, et al.Mechanism of Acid hypersecretion post curative gastrinoma resection. Dig Dis Sci2011;56:139. CrossRef

277. MatonPN, FruchtH, VinayekR, et al.Medical management of patients with Zollinger‐Ellison syndrome who have had previous gastric surgery: a prospective study. Gastroenterology1988;94:294.

278. GibrilF, JensenRT. Zollinger‐Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion. Curr Gastroenterol Rep2004;6:454. CrossRef

279. TermaniniB, GibrilF, StewartCA, et al.A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger‐Ellison syndrome. Aliment Pharmacol Ther1996;10:61. CrossRef

280. HirschowitzBI, SimmonsJ, MohnenJ. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger‐Ellison syndrome: a 13‐year prospective study. Clin Gastroenterol Hepatol2005;3:39. CrossRef

281. HowardJM, ChremosAN, CollenMJ, et al.Famotidine, a new, potent, long‐acting histamine H2‐receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger‐Ellison syndrome. Gastroenterology1985;88:1026.

282. CollenMJ, HowardJM, McArthurKE, et al.Comparison of ranitidine and cimetidine in the treatment of gastric hypersecretion. Ann Intern Med1984;100:52. CrossRef

283. HeidelbaughJJ, MetzDC, YangYX. Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk?Int J Clin Pract2012;66:582. CrossRef

284. FruchtH, MatonPN, JensenRT. Use of omeprazole in patients with the Zollinger‐Ellison syndrome. Dig Dis Sci1991;36:394. CrossRef

285. YangYX, MetzDC. Safety of proton pump inhibitor exposure. Gastroenterology2010;139:1115. CrossRef

286. ItoT, JensenRT. Association of long‐term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin b(12), iron, and magnesium. Curr Gastroenterol Rep2010;12:448. CrossRef

287. JensenRT. Consequences of long‐term proton pump blockade: highlighting insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol2006;98:4. CrossRef

288. TermaniniB, GibrilF, SutliffVEIII, et al.Effect of long‐term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger‐Ellison syndrome. Am J Med1998;104:422. CrossRef

289. HirschowitzBI, WorthingtonJ, MohnenJ. Vitamin B12 deficiency in hypersecretors during long‐term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther2008;27:1110. CrossRef

290. StewartCA, TermaniniB, SutliffVE, et al.Assessment of the risk of iron malabsorption in patients with Zollinger‐Ellison syndrome treated with long‐term gastric acid antisecretory therapy. Aliment Pharmacol Ther1998;12:83. CrossRef

291. YangYX, LewisJD, EpsteinS, et al.Long‐term proton pump inhibitor therapy and risk of hip fracture. JAMA2006;296:2947. CrossRef

292. ScherublH, CadiotG, JensenRT, et al.Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems?Endoscopy2010;42:664. CrossRef

293. MetzDC, PisegnaJR, FishbeynVA, et al.Control of gastric acid hypersecretion in the management of patients with Zollinger‐Ellison syndrome. World J Surg1993;17:468. CrossRef

294. MetzDC, ForsmarkC, LewEA, et al.Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger‐Ellison syndrome. Am J Gastroenterol2001;96:3274. CrossRef

295. VinayekR, FruchtH, LondonJF, et al.Intravenous omeprazole in patients with Zollinger‐Ellison syndrome undergoing surgery. Gastroenterology1990;99:10.

296. PangSH, GrahamDY. A clinical guide to using intravenous proton‐pump inhibitors in reflux and peptic ulcers. Therap Adv Gastroenterol2010;3:11. CrossRef

297. McCarthyDM. The place of surgery in the Zollinger‐Ellison syndrome. N Engl J Med1980;302:1344. CrossRef

298. HirschowitzBI. Clinical course of nonsurgically treated Zollinger‐Ellison syndrome. In: MignonM, JensenRT(eds). Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, Vol. 23. Basel, Switzerland: S. Karger; 1995: 360.

299. LorenzK, DralleH. Surgical treatment of sporadic gastrinoma. Wien Klin Wochenschr2007;119:597. CrossRef

300. FrakerDL, NortonJA, AlexanderHR, et al.Surgery in Zollinger‐Ellison syndrome alters the natural history of gastrinoma. Ann Surg1994;220:320. CrossRef

301. NortonJA, FrakerDL, AlexanderHR, et al.Surgery increases survival in patients with gastrinoma. Ann Surg2006;244:410.

302. FruchtH, NortonJA, LondonJF, et al.Detection of duodenal gastrinomas by operative endoscopic transillumination: a prospective study. Gastroenterology1990;99:1622.

303. LopezCL, FalconiM, WaldmannJ, et al.Partial pancreaticoduodenectomy can provide cure for duodenal gastrinoma associated with multiple endocrine neoplasia type 1. Ann Surg2013;257:308. CrossRef

304. NortonJA, AlexanderHR, FrakerDL, et al.Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger‐Ellison syndrome. Ann Surg2001;234:495. CrossRef

305. MacFarlaneMP, FrakerDL, AlexanderHR, et al.A prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia‐Type 1. Surgery1995;118:973. CrossRef

306. Pipeleers‐MarichalM, SomersG, WillemsG, et al.Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger‐Ellison syndrome. N Engl J Med1990;322:723. CrossRef

307. AnlaufM, GarbrechtN, HenoppT, et al.Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico‐pathological and epidemiological features. World J Gastroenterol2006;12:5440.

308. TriponezF, GoudetP, DossehD, et al.Is surgery beneficial for MEN1 patients with small (< or =2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg2006;30:654. CrossRef

309. MignonM, CadiotG. Natural history of gastrinoma: lessons from the past. Ital J Gastroenterol Hepatol1999;31:S98.

310. KrampitzGW, NortonJA, PoultsidesGA, et al.Lymph nodes and survival in duodenal and pancreatic neuroendocrine tumors. Arch Surg2012;147:820. CrossRef

311. MatonPN, GardnerJD, JensenRT. Cushing's syndrome in patients with Zollinger‐Ellison syndrome. N Engl J Med1986;315:1. CrossRef

312. NortonJA, SugarbakerPH, DoppmanJL, et al.Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Ann Surg1986;203:352. CrossRef

313. QueFG, SarmientoJM, NagorneyDM. Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. Adv Exp Med Biol2006;574:43. CrossRef

314. SarmientoJM, QueFG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin North Am2003;12:231. CrossRef

315. WangSC, FidelmanN, NakakuraEK. Management of well‐differentiated gastrointestinal neuroendocrine tumors metastatic to the liver. Semin Oncol2013;40:69. CrossRef

316. PavelM, BaudinE, CouvelardA, et al.ENETS Consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology2012;95:157. CrossRef

317. RamageJK, AhmedA, ArdillJ, et al.Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut2012;61:6. CrossRef

318. O'TooleD, RuszniewskiP. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol2005;19:585. CrossRef

319. The NCCN Clinical Practice Guidelines in Oncology for Neuroendocrine tumors. Version 1. 2012. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

320. KvolsLK, TuragaKK, StrosbergJ, et al.Role of interventional radiology in the treatment of patients with neuroendocrine metastases in the liver. J Natl Compr Canc Netw2009;7:765.

321. VoglTJ, NaguibNN, ZangosS, et al.Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol2009;72:517. CrossRef

322. NazarioJ, GuptaS. Transarterial liver‐directed therapies of neuroendocrine hepatic metastases. Semin Oncol2010;37:118. CrossRef

323. MemonK, LewandowskiRJ, MulcahyMF, et al.Radioembolization for neuroendocrine liver metastases: safety, imaging, and long‐term outcomes. Int J Radiat Oncol Biol Phys2012;83:887. CrossRef

324. KennedyA, ColdwellD, SangroB, et al.Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver. Am J Clin Oncol2012;35:293. CrossRef

325. PaprottkaPM, HoffmannRT, HaugA, et al.Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium‐90 microspheres. Cardiovasc Intervent Radiol2012;35:334. CrossRef

326. LacinS, OzI, OzkanE, et al.Intra‐arterial treatment with 90yttrium microspheres in treatment‐refractory and unresectable liver metastases of neuroendocrine tumors and the use of 111in‐octreotide scintigraphy in the evaluation of treatment response. Cancer Biother Radiopharm2011;26:631. CrossRef

327. ShaheenM, HassanainM, AljiffryM, et al.Predictors of response to radio‐embolization (TheraSphere(R)) treatment of neuroendocrine liver metastasis. HPB (Oxford)2012;14:60. CrossRef

328. KingJ, QuinnR, GlennDM, et al.Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer2008;113:921. CrossRef

329. WhitneyR, ValekV, FagesJF, et al.Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: a comparison of efficacy and cost. Oncologist2011;16:594. CrossRef

330. KennedyAS, DezarnWA, McNeillieP, et al.Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y‐microspheres: early results in 148 patients. Am J Clin Oncol2008;31:271. CrossRef

331. SaxenaA, ChuaTC, BesterL, et al.Factors predicting response and survival after yttrium‐90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg2010;251:910. CrossRef

332. HarringTR, NguyenNT, GossJA, et al.Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review. Int J Hepatol2011;2011:1. CrossRef

333. Guillermet‐GuibertJ, LahlouH, PyronnetS, et al.Somatostatin receptors as tools for diagnosis and therapy: molecular aspects. Best Pract Res Clin Gastroenterol2005;19:535. CrossRef

334. SteinmullerT, KianmaneshR, FalconiM, et al.Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology2008;87:47. CrossRef

335. EliasD, GoereD, LerouxG, et al.Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. Eur J Surg Oncol2009;35:1092. CrossRef

336. KarabulutK, AkyildizHY, LanceC, et al.Multimodality treatment of neuroendocrine liver metastases. Surgery2011;150:316. CrossRef

337. AkyildizHY, MitchellJ, MilasM, et al.Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long‐term follow‐up. Surgery2010;148:1288. CrossRef

338. ErikssonJ, StalbergP, NilssonA, et al.Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg2008;32:930. CrossRef

339. ToumpanakisC, MeyerT, CaplinME. Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab2007;21:131. CrossRef

340. RiccardiF, RizzoM, FestinoL, et al.Therapy innovation for the treatment of pancreatic neuroendocrine tumors. Expert Opin Ther Targets2012;16:S91. CrossRef

341. KouvarakiMA, AjaniJA, HoffP, et al.Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol2004;22:4762. CrossRef

342. DelaunoitT, DucreuxM, BoigeV, et al.The doxorubicin‐streptozotocin combination for the treatment of advanced well‐differentiated pancreatic endocrine carcinoma; a judicious option?Eur J Cancer2004;40:515. CrossRef

343. KulkeMH. Systemic therapy for advanced pancreatic neuroendocrine tumors. Semin Oncol2013;40:75. CrossRef

344. AppetecchiaM, BaldelliR. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res2010;29:19. CrossRef

345. StrosbergJ, KvolsL. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol2010;16:2963. CrossRef

346. PanzutoF, Di FrancescoV, IannicelliE, et al.Long‐term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well‐differentiated entero‐pancreatic endocrine carcinoma. Ann Oncol2006;17:461. CrossRef

347. PlockingerU, WiedenmannB. Biotherapy. Best Pract Res Clin Endocrinol Metab2007;21:145. CrossRef

348. ShahT, CaplinM. Biotherapy for metastatic endocrine tumours. Best Pract Res Clin Gastroenterol2005;19:617. CrossRef

349. ObergK. Biotherapies for GEP‐NETs. Best Pract Res Clin Gastroenterol2012;26:833. CrossRef

350. ÖbergK. Interferon in the management of neuroendocrine GEP‐tumors. Digestion2000;62:92. CrossRef

351. GedalyR, DailyMF, DavenportD, et al.Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg2011;146:953. CrossRef

352. MatheZ, TagkalosE, PaulA, et al.Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival‐based analysis. Transplantation2011;91:575. CrossRef

353. Le TreutYP, GregoireE, KlempnauerJ, et al.Liver Transplantation for neuroendocrine tumors in Europe – results and trends in patient selection: a 213‐case European liver transplant registry study. Ann Surg2013;257:807. CrossRef

354. FazioN, CinieriS, LorizzoK, et al.Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. Cancer Treat Rev2010;36:S87. CrossRef

355. de WildeRF, EdilBH, HrubanRH, et al.Well‐differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nat Rev Gastroenterol Hepatol2012;9:199. CrossRef

356. YaoJC. Molecular targeted therapy for carcinoid and islet‐cell carcinoma. Best Pract Res Clin Endocrinol Metab2007;21:163. CrossRef

357. CapdevilaJ, SalazarR. Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors. Target Oncol2009;4:287. CrossRef

358. RaymondE, DahanL, RaoulJL, et al.Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med2011;364:501. CrossRef

359. FaivreS, SablinMP, DreyerC, et al.Novel anticancer agents in clinical trials for well‐differentiated neuroendocrine tumors. Endocrinol Metab Clin North Am2010;39:811. CrossRef

360. RaymondE, HobdayT, CastellanoD, et al.Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. Cancer Metastasis Rev2011;30:19. CrossRef

361. KulkeMH, LenzHJ, MeropolNJ, et al.Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol2008;26:3403. CrossRef

362. BergsmaH, van VlietEI, TeunissenJJ, et al.Peptide receptor radionuclide therapy (PRRT) for GEP‐NETs. Best Pract Res Clin Gastroenterol2012;26:867. CrossRef

363. van VlietEI, TeunissenJJ, KamBL, et al.Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy. Neuroendocrinology2013;97:74. CrossRef

364. KwekkeboomDJ, TeunissenJJ, BakkerWH, et al.Radiolabeled somatostatin analog [177Lu‐DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol2005;23:2754. CrossRef

365. Van EssenM, KrenningEP, KamBL, et al.Peptide‐receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol2009;5:382. CrossRef

366. TouziosJG, KielyJM, PittSC, et al.Neuroendocrine hepatic metastases: does aggressive management improve survival?Ann Surg2005;241:776. CrossRef

367. NortonJA. Surgical treatment of neuroendocrine metastases. Best Pract Res Clin Gastroenterol2005;19:577. CrossRef

368. GlazerES, TsengJF, Al‐RefaieW, et al.Long‐term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford)2010;12:427. CrossRef

369. MazzagliaPJ, BerberE, MilasM, et al.Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10‐year experience evaluating predictors of survival. Surgery2007;142:10. CrossRef

370. KunzPL, Reidy‐LagunesD, AnthonyLB, et al.Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas2013;42:557. CrossRef

371. MaireF, Lombard‐BohasC, O'TooleD, et al.Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well‐differentiated midgut endocrine tumors: a prospective randomized study. Neuroendocrinology2012;96:294. CrossRef

372. LewisMA, JaramilloS, RobertsL, et al.Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications. Oncologist2012;17:725. CrossRef

373. GerasimouGP, AggelopoulouT, PapanastasiouE, et al.[Indium‐111‐DTPA‐phenyl‐pentetreotide somatostatin receptors' scintigraphy in the evaluation of patients with suspected gastro‐entero‐pancreatic tumors. Comparison with computerized tomography]. Hell J Nucl Med2007;10:209.

374. RheeTK, LewandowskiRJ, LiuDM, et al.90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi‐institutional experience. Ann Surg2008;247:1029. CrossRef

375. DeleporteA, FlamenP, HendliszA. State of the art: radiolabeled microspheres treatment for liver malignancies. Expert Opin Pharmacother2010;11:579. CrossRef

376. VyletaM, ColdwellD. Radioembolization in the treatment of neuroendocrine tumor metastases to the liver. Int J Hepatol2011;2011:1. CrossRef

377. LeeE, Leon PachterH, SarpelU. Hepatic arterial embolization for the treatment of metastatic neuroendocrine tumors. Int J Hepatol2012;2012:1.

378. CostaFP, GumzB, PascheB. Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol2012;26:843. CrossRef

379. NilssonO, Van CutsemE, Delle FaveG, et al.Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology2006;84:212. CrossRef

380. O'TooleD, HenticO, CorcosO, et al.Chemotherapy for gastro‐enteropancreatic endocrine tumours. Neuroendocrinology2004;80:79. CrossRef

381. RuszniewskiP, HochlafS, RougierP, et al.[Intravenous chemotherapy with streptozotocin and 5 fluorouracil for hepatic metastases of Zollinger‐Ellison syndrome. A prospective multicenter study in 21 patients]. Gastroenterol Clin Biol1991;15:393.

382. von SchrenckT, HowardJM, DoppmanJL, et al.Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology1988;94:1326.

383. EkebladS, SundinA, JansonET, et al.Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res2007;13:2986. CrossRef

384. StrosbergJR, FineRL, ChoiJ, et al.First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer2011;117:268. CrossRef

385. MaireF, HammelP, FaivreS, et al.Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors. Neuroendocrinology2009;90:67. CrossRef

386. KulkeMH, HornickJL, FrauenhofferC, et al.O6‐methylguanine DNA methyltransferase deficiency and response to temozolomide‐based therapy in patients with neuroendocrine tumors. Clin Cancer Res2009;15:338. CrossRef

387. StrosbergJR, CoppolaD, KlimstraDS, et al.The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high‐grade) extrapulmonary neuroendocrine carcinomas. Pancreas2010;39:799. CrossRef

388. SmithJ, Reidy‐LagunesD. The management of extrapulmonary poorly differentiated (high‐grade) neuroendocrine carcinomas. Semin Oncol2013;40:100. CrossRef

389. OlsenIH, LangerSW, JepsenI, et al.First‐line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience. Acta Oncol2012;51:97. CrossRef

390. IwasaS, MorizaneC, OkusakaT, et al.Cisplatin and etoposide as first‐line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol2010;40:313. CrossRef

391. SiderisL, DubeP, RinkeA. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist2012;17:747. CrossRef

392. ModlinIM, PavelM, KiddM, et al.Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther2010;31:169.

393. ToumpanakisC, CaplinME. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Semin Oncol2013;40:56. CrossRef

394. RinkeA, MullerHH, Schade‐BrittingerC, et al.Placebo‐controlled, double‐blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol2009;27:4656. CrossRef

395. CaplinM, RuszniewskiP, PavelM, et al.A randomized, double‐blind, placebo‐controlled study of Lanreotide Antiproliferative Response in patients with gastroenteropancreatic NeuroEndocrine Tumors (CLARINET). 2013 European Cancer Congress, Abstract 3, presented September 28, 2013.

396. ShojamaneshH, GibrilF, LouieA, et al.Prospective study of the anti‐tumor efficacy of long‐term octreotide treatment in patients with progressive metastatic gastrinomas. Cancer2002;94:331. CrossRef

397. PisegnaJR, SlimakGG, DoppmanJL, et al.An evaluation of human recombinant alpha interferon in patients with metastatic gastrinoma. Gastroenterology1993;105:1179.

398. FazioN, de BraudF, Delle FaveG, et al.Interferon‐alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?Ann Oncol2007;18:13. CrossRef

399. CingarliniS, BonomiM, CorboV, et al.Profiling mTOR pathway in neuroendocrine tumors. Target Oncol.2012;7:183. CrossRef

400. CapursoG, FazioN, FestaS, et al.Molecular target therapy for gastroenteropancreatic endocrine tumours: biological rationale and clinical perspectives. Crit Rev Oncol Hematol2009;72:110. CrossRef

401. Grozinsky‐GlasbergS, PavelM. Inhibition of mTOR in carcinoid tumors. Target Oncol2012;7:189. CrossRef

402. JensenRT, Delle FaveG. Promising advances in the treatment of malignant pancreatic endocrine tumors. N Engl J Med2011;364:564. CrossRef

403. FjallskogML, LejonklouMH, ObergKE, et al.Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res2003;9:1469.

404. GilbertJA, AdhikariLJ, LloydRV, et al.Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. Endocr Relat Cancer2010;17:623. CrossRef

405. PavelME, WiedenmannB. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors. Horm Metab Res2011;43:844. CrossRef

406. ItoT, OkusakaT, NishidaT, et al.Phase II study of sunitinib in Japanese patients with unresectable or metastatic well‐differentiated pancreatic neuroendocrine tumors. Invest New Drugs2013;31:1265. CrossRef

407. KwekkeboomDJ, de HerderWW, KrenningEP. Somatostatin receptor‐targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am2011;40:173. CrossRef

408. KwekkeboomDJ, de HerderWW, KamBL, et al.Treatment with the radiolabeled somatostatin analog [177 Lu‐DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol2008;26:2124. CrossRef

409. ForrerF, ValkemaR, KwekkeboomDJ, et al.Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab2007;21:111. CrossRef

410. Grozinsky‐GlasbergS, BarakD, FraenkelM, et al.Peptide receptor radioligand therapy is an effective treatment for the long‐term stabilization of malignant gastrinomas. Cancer2011;117:1377. CrossRef

411. ObergK, JelicS. Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow‐up. Ann Oncol2009;20:147.

412. PascherA, KluppJ, NeuhausP. Transplantation in the management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol2005;19:637. CrossRef

413. Le TreutYP, GregoireE, BelghitiJ, et al.Predictors of long‐term survival after liver transplantation for metastatic endocrine tumors: an 85‐case French multicentric report. Am J Transplant2008;8:1205. CrossRef

414. GregoireE, Le TreutYP. Liver transplantation for primary or secondary endocrine tumors. Transpl Int2010;23:704. CrossRef

415. AhlmanH, FrimanS, CahlinC, et al.Liver transplantation for treatment of metastatic neuroendocrine tumors. Ann N Y Acad Sci2004;1014:265. CrossRef

416. HillJS, McPheeJT, McDadeTP, et al.Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer2009;115:741. CrossRef

417. AsgharianB, TurnerML, GibrilF, et al.Cutaneous tumors in patients with MEN1 and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity. J Clin Endocrinol Metab2004;89:5328. CrossRef

418. AsgharianB, ChenYJ, PatronasNJ, et al.Meningiomas may be a component tumor of MEN1. Clin Cancer Res2004;10:869. CrossRef

419. GibrilF, ChenY‐J, SchrumpDS, et al.Prospective study of thymic carcinoids in patients with Multiple Endocrine Neoplasia Type 1. J Clin Endocrinol Metab2003;88:1066. CrossRef

420. CadiotG, VuagnatA, DoukhanI, et al.Prognostic factors in patients with Zollinger‐Ellison syndrome and multiple endocrine neoplasia type 1. Gastroenterology1999;116:286. CrossRef

421. ZollingerRM. The Zollinger‐Ellison syndrome. World J Surg1981;5:773. CrossRef

422. ZollingerRM. Gastrinoma: factors influencing prognosis. Surgery1985;97:49.

423. MetzDC, KuchnioM, FrakerDL, et al.Flow cytometry and Zollinger‐Ellison syndrome: relationship to clinical course. Gastroenterology1993;105:799.

424. ChenY‐J, ZortmeyerA, ZhuangZP, et al.Chromosome X loss of heterozygosity frequently occurs in gastrinomas and is correlated with aggressive tumor growth. Cancer2004;100:1379. CrossRef

425. ChenYJ, VortmeyerA, ZhuangZ, et al.Loss of heterozygosity of chromosome 1q in gastrinomas: occurrence and prognostic significance. Cancer Res2003;63:817.

426. LepageC, RachetB, ColemanMP. Survival from malignant digestive endocrine tumors in England and Wales: a population‐based study. Gastroenterology2007;132:899. CrossRef

427. ArnoldR, RinkeA, KloseKJ, et al.Octreotide versus octreotide plus interferon‐alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol2005;3:761. CrossRef

428. StrosbergJ, GardnerN, KvolsL. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid‐gut. Neuroendocrinology2009;89:471. CrossRef

429. StrosbergJR, CheemaA, WeberJ, et al.Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol2011;29:3044. CrossRef

430. SchmittAM, AnlaufM, RoussonV, et al.WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol2007;31:1677. CrossRef

431. La RosaS, KlersyC, UccellaS, et al.Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol2009;40:30. CrossRef

432. La RosaS, RigoliE, UccellaS, et al.Prognostic and biological significance of cytokeratin 19 in pancreatic endocrine tumours. Histopathology2007;50:597. CrossRef

433. La RosaS, SessaF, CapellaC, et al.Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch1996;429:323. CrossRef

434. PapeUF, JannH, Muller‐NordhornJ, et al.Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer2008;113:256. CrossRef